Safety, tolerability, and nonglycemic effects of incretin-based therapies

R. Keith Campbell; Michael E. Cobble; Timothy S. Reid; Mansur E. Shomali

Safety, tolerability, and nonglycemic effects of incretin-based therapies

R. Keith Campbell, Michael E. Cobble, Timothy S. Reid, Mansur E. Shomali

Research output: Contribution to journal › Review article › peer-review

Abstract

The overall safety profiles of GLP-1 agonists and DPP-4 inhibitors are favorable, with a low incidence of hypoglycemia. This attribute, along with their weight and cardiovascular benefits, particularly with the GLP-1 agonists, make them appropriate choices in our 3 patient cases. Ongoing safety investigations with GLP-1 agonists and DPP-4 inhibitors will provide further clarity to the complete safety profiles of these agents.

Original language	English (US)
Pages (from-to)	S20-S27
Journal	Journal of Family Practice
Volume	59
Issue number	9 SUPPL. 1
State	Published - Sep 2010
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Cite this

@article{7e22fe7de715432698c651b282ec2e06,

title = "Safety, tolerability, and nonglycemic effects of incretin-based therapies",

abstract = "The overall safety profiles of GLP-1 agonists and DPP-4 inhibitors are favorable, with a low incidence of hypoglycemia. This attribute, along with their weight and cardiovascular benefits, particularly with the GLP-1 agonists, make them appropriate choices in our 3 patient cases. Ongoing safety investigations with GLP-1 agonists and DPP-4 inhibitors will provide further clarity to the complete safety profiles of these agents.",

author = "Campbell, {R. Keith} and Cobble, {Michael E.} and Reid, {Timothy S.} and Shomali, {Mansur E.}",

year = "2010",

month = sep,

language = "English (US)",

volume = "59",

pages = "S20--S27",

journal = "Journal of Family Practice",

issn = "0094-3509",

publisher = "Appleton-Century-Crofts",

number = "9 SUPPL. 1",

}

TY - JOUR

T1 - Safety, tolerability, and nonglycemic effects of incretin-based therapies

AU - Campbell, R. Keith

AU - Cobble, Michael E.

AU - Reid, Timothy S.

AU - Shomali, Mansur E.

PY - 2010/9

Y1 - 2010/9

N2 - The overall safety profiles of GLP-1 agonists and DPP-4 inhibitors are favorable, with a low incidence of hypoglycemia. This attribute, along with their weight and cardiovascular benefits, particularly with the GLP-1 agonists, make them appropriate choices in our 3 patient cases. Ongoing safety investigations with GLP-1 agonists and DPP-4 inhibitors will provide further clarity to the complete safety profiles of these agents.

AB - The overall safety profiles of GLP-1 agonists and DPP-4 inhibitors are favorable, with a low incidence of hypoglycemia. This attribute, along with their weight and cardiovascular benefits, particularly with the GLP-1 agonists, make them appropriate choices in our 3 patient cases. Ongoing safety investigations with GLP-1 agonists and DPP-4 inhibitors will provide further clarity to the complete safety profiles of these agents.

UR - http://www.scopus.com/inward/record.url?scp=77956665223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956665223&partnerID=8YFLogxK

M3 - Review article

C2 - 20824236

AN - SCOPUS:77956665223

SN - 0094-3509

VL - 59

SP - S20-S27

JO - Journal of Family Practice

JF - Journal of Family Practice

IS - 9 SUPPL. 1

ER -

Safety, tolerability, and nonglycemic effects of incretin-based therapies

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this